Rezolute (RZLT) Accumulated Expenses (2011 - 2026)
Rezolute recorded quarterly Accumulated Expenses of $1.0 million in Q1 2026, down 32.51% quarter-over-quarter from $1.5 million in Q4 2025, and down 0.96% year-over-year from $1.0 million in Q1 2025.
Rezolute's Accumulated Expenses history runs 16 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 0.96% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 0.96% YoY), while the FY2025 annual figure was $2.3 million, up 25.22% from the prior year.
- Accumulated Expenses came in at $1.0 million for Q1 2026 at Rezolute, down from $1.5 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $4.0 million in Q4 2024 to a low of $450000.0 in Q1 2022.
- A 5-year average of $1.9 million and a median of $1.7 million in 2023 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses jumped 150.0% in 2022 and tumbled 61.5% in 2025, its largest moves.
- Rezolute's Accumulated Expenses stood at $2.2 million in 2022, then climbed by 11.15% to $2.5 million in 2023, then jumped by 60.25% to $4.0 million in 2024, then sank by 61.5% to $1.5 million in 2025, then sank by 32.51% to $1.0 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $1.0 million, $1.5 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 3.32 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 3.98 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | 879,000.00 |
| Dec 31, 2023 | 2.48 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 883,000.00 |
| Dec 31, 2022 | 2.23 Mn |
| Mar 31, 2022 | 450,000.00 |
| Dec 31, 2021 | 1.47 Mn |
| Jun 30, 2021 | 77,000.00 |
| Mar 31, 2021 | 180,000.00 |
| Dec 31, 2020 | 1.26 Mn |
| Sep 30, 2020 | 79,000.00 |
| Jun 30, 2020 | 120,000.00 |
| Mar 31, 2020 | 144,000.00 |
| Dec 31, 2019 | 800,000.00 |
| Sep 30, 2019 | 201,000.00 |
| Jun 30, 2019 | 790,000.00 |
| Mar 31, 2019 | 1.16 Mn |
| Dec 31, 2018 | 872,431.00 |
| Sep 30, 2018 | 868,565.00 |
| Jun 30, 2018 | 771,000.00 |
| Mar 31, 2018 | 23,014.00 |
| Dec 31, 2017 | 2,762.00 |
| Sep 30, 2017 | 2,762.00 |
| Jun 30, 2017 | 2,762.00 |
| Mar 31, 2017 | 2,762.00 |
| Dec 31, 2016 | 2,762.00 |
| Sep 30, 2016 | 15,579.00 |
| Jun 30, 2016 | 15,079.00 |
| Mar 31, 2016 | 14,579.00 |
| Dec 31, 2015 | 14,079.00 |
| Sep 30, 2015 | 13,579.00 |
| Jun 30, 2015 | 13,079.00 |
| Mar 31, 2015 | 12,579.00 |
| Dec 31, 2014 | 12,079.00 |
| Sep 30, 2014 | 11,579.00 |
| Jun 30, 2014 | 11,079.00 |
| Mar 31, 2014 | 98,718.00 |
| Dec 31, 2013 | 601,459.00 |
| Sep 30, 2013 | 469,884.00 |
| Jun 30, 2013 | 380,575.00 |
| Mar 31, 2013 | 298,523.00 |
| Jun 30, 2012 | 110,124.00 |
| Dec 31, 2011 | 51,817.00 |